Moolec Science Secures Nasdaq Exception, Boosts Equity by Over $100M via Subsidiary Derecognition

summarizeSummary

Moolec Science SA has received an exception from Nasdaq until June 29, 2026, to regain compliance with listing requirements, reporting an estimated increase of over $100 million in stockholders' equity due to the derecognition of bankrupt subsidiaries.

check_boxKey Events

• Nasdaq Compliance Exception

  Moolec Science SA received an exception from the Nasdaq Hearings Panel until June 29, 2026, to regain compliance with the stockholders' equity requirement, mitigating immediate delisting concerns.

• Significant Equity Increase

  The company reported an estimated increase of approximately $100.8 million in stockholders' equity, which it believes brings it into compliance with Nasdaq's listing rules.

• Derecognition of Bankrupt Subsidiaries

  This equity increase stems from accounting gains recognized due to the loss of control over subsidiaries Bioceres S.A., Bioceres LLC, and Theo I SCSp, following their bankruptcy proceedings in December 2025.

auto_awesomeAnalysis

The Nasdaq Hearings Panel granted Moolec Science an exception, extending its deadline to meet the stockholders' equity requirement until June 29, 2026. This temporary relief from potential delisting is a critical development for the company. Moolec believes it has already regained compliance, attributing an estimated $100.8 million increase in stockholders' equity to accounting gains from the derecognition of subsidiaries (Bioceres S.A., Bioceres LLC, and Theo I SCSp) following their respective bankruptcy proceedings. While the underlying bankruptcies of subsidiaries are negative operational events, the resulting accounting gains significantly improve Moolec's balance sheet and address a key listing compliance issue, providing a positive signal for the company's immediate future on Nasdaq.